LL-37
Human cathelicidin antimicrobial peptide
An endogenous antimicrobial peptide with complex immune, microbial and wound-biology actions.
Mechanism
Innate host-defense and inflammatory signaling
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Human evidence is absent, limited or not confirmatory
Anecdotal schedules are excluded because frequency of online repetition does not establish identity, safety, or a clinically meaningful dose.
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Common conservative cycle schedule | 50–100 mcg | 50–100 mcg/day | Once daily | Consistent daily time | Subcutaneous | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Community-Reported Preparation Notes
Diluent reports, visible-change signals, and formulation sensitivity—kept separate from validated product instructions.
Sterile and bacteriostatic water are both discussed, but no validated universal injectable diluent is established.
Laboratory studies use controlled buffers whose composition should not be translated into human preparation advice.
- Community consistency
- Product-dependent
- Cloudiness / gel signal
- High aggregation sensitivity
Salt concentration, pH, peptide concentration, temperature, time, and contact surfaces.
Published self-association research supports a fragility warning only—not an injectable preparation method.
Visible-change discard rule: Do not use or attempt to salvage material with persistent cloudiness, strings, flakes, precipitate, unusual thickening, or gel formation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
Cycle Structure
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 50–100 mcg | Once daily | 0.35–0.7 mg/week |
Peptide Vials
| Cycle | Total compound | Vials needed | How long one vial lasts |
|---|---|---|---|
| 4 weeks | 1.4–2.8 mg | 1 × 5 mg | 50–100 administrations |
| 8 weeks | 2.8–5.6 mg | 1–2 × 5 mg | 50–100 administrations |
| 12 weeks | 4.2–8.4 mg | 1–2 × 5 mg | 50–100 administrations |
Bacteriostatic Water
| Cycle | Total water used | 10 mL bottles needed |
|---|---|---|
| 4 weeks | 2 mL | 1 × 10 mL |
| 8 weeks | 2–4 mL | 1 × 10 mL |
| 12 weeks | 2–4 mL | 1 × 10 mL |
Insulin Syringes (U-100)
| Cycle | Administrations | Syringes needed |
|---|---|---|
| 4 weeks | 28 | 28 |
| 8 weeks | 56 | 56 |
| 12 weeks | 84 | 84 |
Ranges reflect the low and high ends of the displayed community schedule. Vials and 10 mL water bottles are rounded up; one new U-100 syringe is counted per subcutaneous administration.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Pro-inflammatory, immune and tissue effects are context-dependent; adequate human injection safety data are lacking.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.